Italy
· Delayed Price · Currency is EUR BridgeBio Pharma Statistics
Total Valuation
BIT:1BBIO has a market cap or net worth of EUR 12.20 billion. The enterprise value is 13.25 billion.
| Market Cap | 12.20B |
| Enterprise Value | 13.25B |
Important Dates
The next estimated earnings date is Friday, February 20, 2026.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 192.71M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.48% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 4.29% |
| Owned by Institutions (%) | 83.00% |
| Float | 155.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.46 |
| PB Ratio | -7.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.50 |
| EV / Sales | 43.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -26.53 |
Financial Position
The company has a current ratio of 3.88
| Current Ratio | 3.88 |
| Quick Ratio | 3.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.17 |
| Interest Coverage | -3.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -43.47% |
| Return on Invested Capital (ROIC) | -161.27% |
| Return on Capital Employed (ROCE) | -74.01% |
| Revenue Per Employee | 414,185 |
| Profits Per Employee | -933,219 |
| Employee Count | 730 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BIT:1BBIO has paid 1.46 million in taxes.
| Income Tax | 1.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 53.30 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 66.31 |
| Average Volume (20 Days) | 13 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.95 |
Income Statement
In the last 12 months, BIT:1BBIO had revenue of EUR 301.53 million and -679.38 million in losses. Loss per share was -3.57.
| Revenue | 301.53M |
| Gross Profit | 288.79M |
| Operating Income | -493.03M |
| Pretax Income | -685.24M |
| Net Income | -679.38M |
| EBITDA | -488.45M |
| EBIT | -493.03M |
| Loss Per Share | -3.57 |
Balance Sheet
The company has 550.54 million in cash and 1.59 billion in debt, giving a net cash position of -1.03 billion.
| Cash & Cash Equivalents | 550.54M |
| Total Debt | 1.59B |
| Net Cash | -1.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.64B |
| Book Value Per Share | -8.55 |
| Working Capital | 530.80M |
Cash Flow
In the last 12 months, operating cash flow was -498.44 million and capital expenditures -946,905, giving a free cash flow of -499.39 million.
| Operating Cash Flow | -498.44M |
| Capital Expenditures | -946,905 |
| Free Cash Flow | -499.39M |
| FCF Per Share | n/a |
Margins
Gross margin is 95.78%, with operating and profit margins of -163.51% and -225.31%.
| Gross Margin | 95.78% |
| Operating Margin | -163.51% |
| Pretax Margin | -227.26% |
| Profit Margin | -225.31% |
| EBITDA Margin | -161.99% |
| EBIT Margin | -163.51% |
| FCF Margin | n/a |
Dividends & Yields
BIT:1BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.48% |
| Shareholder Yield | -4.48% |
| Earnings Yield | -5.57% |
| FCF Yield | -4.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIT:1BBIO has an Altman Z-Score of -4.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.49 |
| Piotroski F-Score | 3 |